Clinical Trials Browser

Phase 1 × Endometrial Neoplasms × Lapatinib × Clear all

NCT01454479 2011-10-19

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Phase 1 Unknown

Endometrial Neoplasms